Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.72 |
| ▸ | PIK3CB | P42338 | 17/20 | 0.72 |
| ▸ | PIK3CD | O00329 | 17/20 | 0.72 |
| ▸ | MTOR | P42345 | 16/20 | 0.72 |
| ▸ | PIK3CG | P48736 | 16/20 | 0.72 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.72 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.72 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29959335 | 1.00 | PIK3CA (0.72) | PIK3CAPIK3CBPIK3CDMTORPIK3CG | |
| Hydrochloric Acid SCHEMBL17822195 | 0.99 | PIK3CA (0.71) | PIK3CAPIK3CBPIK3CDMTORPIK3CG | |
| SCHEMBL17822217 | 0.98 | PIK3CA (0.69) | PIK3CAPIK3CBPIK3CDMTORPIK3CG | |
| Water SCHEMBL27149496 | 0.97 | PIK3CA (0.69) | PIK3CAPIK3CBPIK3CDMTORPIK3CG | |
| SCHEMBL19549656 | 0.87 | PIK3CA (0.55) | PIK3CAPIK3CBPIK3CDMTORPIK3CG | |
| SCHEMBL17822198 | 0.87 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CDMTORPIK3CG | |
| SCHEMBL19564906 | 0.85 | PIK3CA (0.55) | PIK3CAPIK3CBPIK3CDMTORPIK3CG | |
| SCHEMBL17822190 | 0.84 | PIK3CA (0.74) | PIK3CAPIK3CBPIK3CDMTORPIK3CG | |
| SCHEMBL1180950 | 0.84 | PIK3CA (1.00) | PIK3CAPIK3CBPIK3CDMTORPIK3CG | |
| SCHEMBL29367908 | 0.84 | PIK3CA (1.00) | PIK3CAPIK3CBPIK3CDMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199637-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | NATCO PHARMA LIMITED (IN) | 2024-06-20 | — | — | US | claimed |
| EP-4326276-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | Natco Pharma Ltd (IN) | 2024-02-28 | — | — | EP | claimed |
| CN-117529325-A | Improved process for preparing 7- (morpholinyl) -2- (N-piperazinyl) methylthio [2,3-c ] pyridine derivatives | 纳特科药品有限公司 | 2024-02-06 | — | — | CN | claimed |
| EP-3230289-B1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LTD (IN) | 2019-08-14 | — | — | EP | claimed |
| US-10106554-B2 | 7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-C] pyridine derivatives as anticancer drugs | NATCO PHARMA LIMITED (IN) | 2018-10-23 | — | — | US | claimed |
| US-20170320891-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2017-11-09 | — | — | US | claimed |
| EP-3230289-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | Natco Pharma Limited (IN) | 2017-10-18 | — | — | EP | claimed |
| WO-2016092556-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2016-06-16 | — | — | WO | claimed |
| US-20240199637-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | NATCO PHARMA LIMITED (IN) | 2024-06-20 | — | — | US | disclosed |
| US-20240199637-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | NATCO PHARMA LIMITED (IN) | 2024-06-20 | — | — | US | disclosed |
| EP-4326276-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | Natco Pharma Ltd (IN) | 2024-02-28 | — | — | EP | disclosed |
| EP-4326276-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | Natco Pharma Ltd (IN) | 2024-02-28 | — | — | EP | disclosed |
| CN-117529325-A | Improved process for preparing 7- (morpholinyl) -2- (N-piperazinyl) methylthio [2,3-c ] pyridine derivatives | 纳特科药品有限公司 | 2024-02-06 | — | — | CN | disclosed |
| WO-2022224267-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | NATCO PHARMA LIMITED (IN) | 2022-10-27 | — | — | WO | disclosed |
| US-20170320891-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2017-11-09 | — | — | US | disclosed |
| US-20170320891-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2017-11-09 | — | — | US | disclosed |
| US-20170320891-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2017-11-09 | — | — | US | disclosed |
| EP-3230289-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | Natco Pharma Limited (IN) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016092556-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016092556-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106554-B2 | 7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-C] pyridine derivatives as anticancer drugs | PRMT7, CDK7, CASP7 | PIK3CA 1853/4885PIK3CB 2087/4885PIK3CD 2109/4885 |
| US-20240199637-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | NR2C2, NRDC, NDC1 | PIK3CA 1439/4885PIK3CB 776/4885PIK3CD 975/4885 |
| US-20170320891-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | PRMT7, CDK7, CASP7 | PIK3CA 1853/4885PIK3CB 2087/4885PIK3CD 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.